Shoufeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shoufeng Wang has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Jin Xiong
Department of Orthopedic Surgery The Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing China
7 shared publicationsLeilei Xu
Department of Orthopedic Surgery The Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing China
7 shared publicationsQi Sun
Department of Pathology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321, Nanjing 210008, China
4 shared publications- Binghao Li
Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications Chao Xia
Department of Orthopedic Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321, Nanjing 210008, China
3 shared publicationsFei Sheng
Department of Orthopedic Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321, Nanjing 210008, China
3 shared publications
Latest Publications
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Data from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
Purpose:Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma.Patients and Methods:Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases. Anlotinib was given orally at a dose of 12 mg once daily from days 1 to 14 every 3 weeks until disease progression or intolerable adverse events (AE) occurred. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate, and disease control rate (DCR). The safety profile was also evaluated.Results:Forty patients were enrolled from April 2019 to June 2022 and are included in the intention-to-treat analysis. The median PFS was 6.83 months [95% confidence interval (CI), 4.17–8.71] and the median OS 27.40 months (95% CI, 16.43–not evaluable); 1 patient reached partial response and 26 attained stable disease, with a DCR of 67.5% (27/40). Median PFS and OS times for liposarcoma patients were 8.71 and 16.23 months, respectively. Ten (25.0%) patients had treatment-related AEs ≥ grade 3, with in particular a higher incidence of hypertension (15.0%) and proteinuria (7.5%).Conclusions:The findings suggest a potential benefit in using front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the liposarcoma subgroup of patients were encouraging.See related commentary by Napolitano et al., p. 4257
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
Purpose:Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma.Patients and Methods:Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases. Anlotinib was given orally at a dose of 12 mg once daily from days 1 to 14 every 3 weeks until disease progression or intolerable adverse events (AE) occurred. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate, and disease control rate (DCR). The safety profile was also evaluated.Results:Forty patients were enrolled from April 2019 to June 2022 and are included in the intention-to-treat analysis. The median PFS was 6.83 months [95% confidence interval (CI), 4.17–8.71] and the median OS 27.40 months (95% CI, 16.43–not evaluable); 1 patient reached partial response and 26 attained stable disease, with a DCR of 67.5% (27/40). Median PFS and OS times for liposarcoma patients were 8.71 and 16.23 months, respectively. Ten (25.0%) patients had treatment-related AEs ≥ grade 3, with in particular a higher incidence of hypertension (15.0%) and proteinuria (7.5%).Conclusions:The findings suggest a potential benefit in using front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the liposarcoma subgroup of patients were encouraging.See related commentary by Napolitano et al., p. 4257
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
Supplementary File 1. Inclusion and exclusion criteria.Supplementary Table S1. Representativeness of trial patients.Supplementary Table S2. Summary of adverse events.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
Supplementary File 1. Inclusion and exclusion criteria.Supplementary Table S1. Representativeness of trial patients.Supplementary Table S2. Summary of adverse events.
- Top Cited PapersOpen Access
- 14 March 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (19) , 4310-4317
First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
Purpose: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma. Patients and Methods: Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases. Anlotinib was given orally at a dose of 12 mg once daily from days 1 to 14 every 3 weeks until disease progression or intolerable adverse events (AE) occurred. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate, and disease control rate (DCR). The safety profile was also evaluated. Results: Forty patients were enrolled from April 2019 to June 2022 and are included in the intention-to-treat analysis. The median PFS was 6.83 months [95% confidence interval (CI), 4.17–8.71] and the median OS 27.40 months (95% CI, 16.43–not evaluable); 1 patient reached partial response and 26 attained stable disease, with a DCR of 67.5% (27/40). Median PFS and OS times for liposarcoma patients were 8.71 and 16.23 months, respectively. Ten (25.0%) patients had treatment-related AEs ≥ grade 3, with in particular a higher incidence of hypertension (15.0%) and proteinuria (7.5%). Conclusions: The findings suggest a potential benefit in using front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the liposarcoma subgroup of patients were encouraging. See related commentary by Napolitano et al., p. 4257
- 14 March 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (19) , 4310-4317
Top Cited PapersOpen AccessFirst-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
Purpose: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines, but patient tolerance of chemotherapy is limited. The present trial (NCT03792542) investigated the use of anlotinib as first-line treatment for patients with advanced STS, in particular liposarcoma. Patients and Methods: Eligible patients were previously untreated, pathologically confirmed, unresectable LA/M STS cases. Anlotinib was given orally at a dose of 12 mg once daily from days 1 to 14 every 3 weeks until disease progression or intolerable adverse events (AE) occurred. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate, and disease control rate (DCR). The safety profile was also evaluated. Results: Forty patients were enrolled from April 2019 to June 2022 and are included in the intention-to-treat analysis. The median PFS was 6.83 months [95% confidence interval (CI), 4.17–8.71] and the median OS 27.40 months (95% CI, 16.43–not evaluable); 1 patient reached partial response and 26 attained stable disease, with a DCR of 67.5% (27/40). Median PFS and OS times for liposarcoma patients were 8.71 and 16.23 months, respectively. Ten (25.0%) patients had treatment-related AEs ≥ grade 3, with in particular a higher incidence of hypertension (15.0%) and proteinuria (7.5%). Conclusions: The findings suggest a potential benefit in using front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the liposarcoma subgroup of patients were encouraging. See related commentary by Napolitano et al., p. 4257
- RetractedOpen Access
- 31 August 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (26) , e2300877
RETRACTED: Bivalent Gadolinium Ions Forming Injectable Hydrogels for Simultaneous In Situ Vaccination Therapy and Imaging of Soft Tissue Sarcoma
Doxorubicin (DOX) is the classic soft tissue sarcomas (STS) first‐line treatment drug, while dose‐dependent myelosuppression and cardiotoxicity limit its application in clinic. This research intends to apply DOX, which is also an inducer of immunogenic cell death as a part for “in situ vaccination” and conjointly uses PD‐1 inhibitors to enhance antitumor efficacy. In order to achieve the sustained vaccination effect and real‐time monitoring of distribution in vivo, the in situ forming and injectable hydrogel platform with the function of visualization is established for local delivery. The hydrogel platform is synthesized by hyaluronic acid‐dopamine coordinated with gadolinium ions (Gd 2+ ). Gd 2+ provides the ability of magnetic resonance imaging, meanwhile further cross‐linking the hydrogel network. Experiments show excellent ability of sustained release and imaging tracking for the hydrogel platform. In mouse STS models, the “in situ vaccination” hydrogels show the best effect of inhibiting tumor growth. Further analysis of tumor tissues show that “in situ vaccination” group can increase T cell infiltration, promote M1‐type macrophage polarization and block elevated PD‐1/PD‐L1 pathway caused by DOX. These results are expected to prove the potential for synthesized hydrogels to achieve a universal platform for “in situ vaccination” strategies on STS treatments.
- 31 August 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (26) , e2300877
RetractedOpen AccessRETRACTED: Bivalent Gadolinium Ions Forming Injectable Hydrogels for Simultaneous In Situ Vaccination Therapy and Imaging of Soft Tissue Sarcoma
Doxorubicin (DOX) is the classic soft tissue sarcomas (STS) first‐line treatment drug, while dose‐dependent myelosuppression and cardiotoxicity limit its application in clinic. This research intends to apply DOX, which is also an inducer of immunogenic cell death as a part for “in situ vaccination” and conjointly uses PD‐1 inhibitors to enhance antitumor efficacy. In order to achieve the sustained vaccination effect and real‐time monitoring of distribution in vivo, the in situ forming and injectable hydrogel platform with the function of visualization is established for local delivery. The hydrogel platform is synthesized by hyaluronic acid‐dopamine coordinated with gadolinium ions (Gd 2+ ). Gd 2+ provides the ability of magnetic resonance imaging, meanwhile further cross‐linking the hydrogel network. Experiments show excellent ability of sustained release and imaging tracking for the hydrogel platform. In mouse STS models, the “in situ vaccination” hydrogels show the best effect of inhibiting tumor growth. Further analysis of tumor tissues show that “in situ vaccination” group can increase T cell infiltration, promote M1‐type macrophage polarization and block elevated PD‐1/PD‐L1 pathway caused by DOX. These results are expected to prove the potential for synthesized hydrogels to achieve a universal platform for “in situ vaccination” strategies on STS treatments.
- Open Access
- 15 July 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (28) , e29550
Postoperative radiotherapy in pIIIA-N2 non–small cell lung cancer after complete resection and adjuvant chemotherapy: A meta-analysis
Background: This study aimed to evaluate the effect of postoperative radiotherapy (PORT) in patients with pIIIA-N2 non–small cell lung cancer after complete resection and adjuvant chemotherapy. Methods: Electronic databases (PubMed, Web of Science databases, Embase, and the Cochrane Central Register of Controlled Trials) were systematically searched to extract randomized control trials comparing PORT with observation in pIIIA-N2 non–small cell lung cancer patients until October 2021. Main outcomes were disease-free survival (DFS), overall survival (OS), and local recurrence. Results: Three-phase 3 randomized control trials involving 902 patients were included: 455 patients in the PORT group and 447 patients in the observation group. The methodological quality of the 3 randomized control trials were high quality. The pooled analysis revealed that PORT decreased local recurrence rate (odds ratio = 0.56, 95% confidence interval [CI]: 0.40–0.76). However, PORT did not improve median DFS (hazard ratio = 0.84, 95% CI: 0.71–1.00) and OS (hazard ratio = 1.02, 95% CI: 0.68–1.52). Conclusions: PORT decreased the incidence of local recurrence. However, PORT did not improve DFS and OS.
- 15 July 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (28) , e29550
Open AccessPostoperative radiotherapy in pIIIA-N2 non–small cell lung cancer after complete resection and adjuvant chemotherapy: A meta-analysis
Background: This study aimed to evaluate the effect of postoperative radiotherapy (PORT) in patients with pIIIA-N2 non–small cell lung cancer after complete resection and adjuvant chemotherapy. Methods: Electronic databases (PubMed, Web of Science databases, Embase, and the Cochrane Central Register of Controlled Trials) were systematically searched to extract randomized control trials comparing PORT with observation in pIIIA-N2 non–small cell lung cancer patients until October 2021. Main outcomes were disease-free survival (DFS), overall survival (OS), and local recurrence. Results: Three-phase 3 randomized control trials involving 902 patients were included: 455 patients in the PORT group and 447 patients in the observation group. The methodological quality of the 3 randomized control trials were high quality. The pooled analysis revealed that PORT decreased local recurrence rate (odds ratio = 0.56, 95% confidence interval [CI]: 0.40–0.76). However, PORT did not improve median DFS (hazard ratio = 0.84, 95% CI: 0.71–1.00) and OS (hazard ratio = 1.02, 95% CI: 0.68–1.52). Conclusions: PORT decreased the incidence of local recurrence. However, PORT did not improve DFS and OS.
- Open Access
- 13 December 2021
- Published by Wiley in Orthopaedic Surgery
- Vol. 14 (2) , 215-220
Reconstruction of Soft Tissue Defect With a Free Vascularized Anterolateral Thigh Flap After Resection of Soft Tissue Sarcoma in Extremities
Objective This study aims to determine outcomes and complications in functional reconstruction of soft tissue defects after surgical resection for soft tissue sarcomas (STSs) of extremities. Methods A retrospective chart review was performed on patients with STSs of extremities from May 2015 to April 2019 who underwent radical resection of STSs and reconstruction of soft tissue defect with free vascularized anterolateral thigh flap (FVALTP). A minimum 3-month follow-up was required for all the patients. Patient demographics and comorbidities, flap characteristics, postoperative complications, and time to heal were recorded. The functional outcomes of the reconstructed limbs were assessed by the Musculoskeletal Tumour Society(MSTS) scoring system. Results A total of 11 patients (four males and seven females) were included in the study. The mean age was 62 years (range: 29–84 years). The mean surface area was 151.4 cm2 (range: from 64 cm2 to 418cm2). The mean operation time was 126 min (range: 95–296 min). The mean follow-up was 17.5 months (range: 6–34 months). The mean score of MSTS at last follow-up was 26.2 (range: 12–29). Incision healed by first intention in eight patients. Incision healed by second intention in three patients. A patient who had received preoperative radiotherapy experienced delayed union. After debridement, the patient successfully got union. Another two patients experienced marginal necrosis of flap due to vascular crisis. After 3-week dressing changes, the patients also got satisfactory union. One case suffered from vascular crisis during surgery in which the procedure was changed into skin grafting to cover resection site. Conclusion FVALTP technique can be effectively applied to the reconstruction of soft tissue defect after STSs resection. The short-term follow-up indicated satisfactory functional outcome and low incidence of previously known complications. It was necessary to further validate its efficacy in reconstruction of soft tissue defect after malignant extremity soft tissue sarcoma resection.
- 13 December 2021
- Published by Wiley in Orthopaedic Surgery
- Vol. 14 (2) , 215-220
Open AccessReconstruction of Soft Tissue Defect With a Free Vascularized Anterolateral Thigh Flap After Resection of Soft Tissue Sarcoma in Extremities
Objective This study aims to determine outcomes and complications in functional reconstruction of soft tissue defects after surgical resection for soft tissue sarcomas (STSs) of extremities. Methods A retrospective chart review was performed on patients with STSs of extremities from May 2015 to April 2019 who underwent radical resection of STSs and reconstruction of soft tissue defect with free vascularized anterolateral thigh flap (FVALTP). A minimum 3-month follow-up was required for all the patients. Patient demographics and comorbidities, flap characteristics, postoperative complications, and time to heal were recorded. The functional outcomes of the reconstructed limbs were assessed by the Musculoskeletal Tumour Society(MSTS) scoring system. Results A total of 11 patients (four males and seven females) were included in the study. The mean age was 62 years (range: 29–84 years). The mean surface area was 151.4 cm2 (range: from 64 cm2 to 418cm2). The mean operation time was 126 min (range: 95–296 min). The mean follow-up was 17.5 months (range: 6–34 months). The mean score of MSTS at last follow-up was 26.2 (range: 12–29). Incision healed by first intention in eight patients. Incision healed by second intention in three patients. A patient who had received preoperative radiotherapy experienced delayed union. After debridement, the patient successfully got union. Another two patients experienced marginal necrosis of flap due to vascular crisis. After 3-week dressing changes, the patients also got satisfactory union. One case suffered from vascular crisis during surgery in which the procedure was changed into skin grafting to cover resection site. Conclusion FVALTP technique can be effectively applied to the reconstruction of soft tissue defect after STSs resection. The short-term follow-up indicated satisfactory functional outcome and low incidence of previously known complications. It was necessary to further validate its efficacy in reconstruction of soft tissue defect after malignant extremity soft tissue sarcoma resection.
- Open Access
- 14 June 2020
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Neuromuscular electrical stimulation for cancer pain in children with osteosarcoma: A protocol of systematic review
INPLASY202060054 Neuromuscular electrical stimulation for cancer pain in children with osteosarcoma: A protocol of systematic review Keywords: Osteosarcoma; neuromuscular electrical stimulation; ca…
- 14 June 2020
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Open AccessNeuromuscular electrical stimulation for cancer pain in children with osteosarcoma: A protocol of systematic review
INPLASY202060054 Neuromuscular electrical stimulation for cancer pain in children with osteosarcoma: A protocol of systematic review Keywords: Osteosarcoma; neuromuscular electrical stimulation; ca…
- Open Access
- 15 May 2020
- Published by Wiley in Orthopaedic Surgery
- Vol. 12 (3) , 727-733
Clinical Outcome of Free Vascularized Fibula Graft in the Surgical Treatment of Extremity Osteosarcoma
Objective: To determine the clinical outcome and complications associated with use of free vascularized fibular graft (FVFG) in the resection and reconstruction of extremity osteosarcoma (OS).Methods: This is a retrospective study recruiting a consecutive series of 18 patients who had undergone resection of extremity OS between May 2009 and June 2017 in our clinic center. Reconstruction of the bone defect with FVFG was performed for each patient. Surgery‐related complications and time of bone union were recorded at the follow‐up visit. The functional outcome of the reconstructed limb was assessed with the musculoskeletal tumor society (MSTS) scoring system. Patients were further classified into low extremity group and upper extremity group according to the tumor location. The Student t‐test was used to compare the surgical outcome between the two subgroups.Results: There were 11 males and seven females with an average age of 25.9 ± 14.2 years. The mean length of the bone resection was 11.9 ± 4.1 cm. The mean follow‐up duration was 3.1 ± 1.2 years. As for tumor location, six cases were located in the femur, five in the tibia, four in the humerus, two in the ulna, and one in the radius. All the patients had successful graft healing at an average of 4.9 months after surgery. At the 2‐year follow‐up, an excellent functional outcome was observed in 88.9% of the patients (n = 16). The mean score of MSTS was 27.0 ± 4.6. Screw loosening and autograft fracture were observed in one patient with femur tumor, who had a low MSTS score of 11. Besides, there were three cases with delayed incision healing. Patients with lower extremity OS were found to have significantly longer duration of hospital stay and more blood loss than those with upper extremity OS. The incidence of postoperative complication was higher in the lower extremity group but with marginal significance (0% vs 36.3%, P = 0.1). There was no significant difference regarding time to bone union and the functional outcome as indicated by MSTS score.Conclusions: FVFG technique can be effectively applied to the reconstruction of bone defects after OS resection with satisfactory functional outcome and low incidence of complications.
- 15 May 2020
- Published by Wiley in Orthopaedic Surgery
- Vol. 12 (3) , 727-733
Open AccessClinical Outcome of Free Vascularized Fibula Graft in the Surgical Treatment of Extremity Osteosarcoma
Objective: To determine the clinical outcome and complications associated with use of free vascularized fibular graft (FVFG) in the resection and reconstruction of extremity osteosarcoma (OS).Methods: This is a retrospective study recruiting a consecutive series of 18 patients who had undergone resection of extremity OS between May 2009 and June 2017 in our clinic center. Reconstruction of the bone defect with FVFG was performed for each patient. Surgery‐related complications and time of bone union were recorded at the follow‐up visit. The functional outcome of the reconstructed limb was assessed with the musculoskeletal tumor society (MSTS) scoring system. Patients were further classified into low extremity group and upper extremity group according to the tumor location. The Student t‐test was used to compare the surgical outcome between the two subgroups.Results: There were 11 males and seven females with an average age of 25.9 ± 14.2 years. The mean length of the bone resection was 11.9 ± 4.1 cm. The mean follow‐up duration was 3.1 ± 1.2 years. As for tumor location, six cases were located in the femur, five in the tibia, four in the humerus, two in the ulna, and one in the radius. All the patients had successful graft healing at an average of 4.9 months after surgery. At the 2‐year follow‐up, an excellent functional outcome was observed in 88.9% of the patients (n = 16). The mean score of MSTS was 27.0 ± 4.6. Screw loosening and autograft fracture were observed in one patient with femur tumor, who had a low MSTS score of 11. Besides, there were three cases with delayed incision healing. Patients with lower extremity OS were found to have significantly longer duration of hospital stay and more blood loss than those with upper extremity OS. The incidence of postoperative complication was higher in the lower extremity group but with marginal significance (0% vs 36.3%, P = 0.1). There was no significant difference regarding time to bone union and the functional outcome as indicated by MSTS score.Conclusions: FVFG technique can be effectively applied to the reconstruction of bone defects after OS resection with satisfactory functional outcome and low incidence of complications.
- Open Access
- 1 February 2020
- Published by Elsevier in Journal of Bone Oncology
- Vol. 20, 100270
Functional variant of IL33 is associated with survival of osteosarcoma patients
- 1 February 2020
- Published by Elsevier in Journal of Bone Oncology
- Vol. 20, 100270
Open AccessFunctional variant of IL33 is associated with survival of osteosarcoma patients
- Open Access
- 1 September 2018
- Published by Elsevier in Journal of Bone Oncology
- Vol. 12, 44-48
Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma
- 1 September 2018
- Published by Elsevier in Journal of Bone Oncology
- Vol. 12, 44-48
Open AccessVariants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma